The role of epidemiology in the regulation of oral contraceptives.
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.

Search our Collections & Repository

All these words:

For very narrow results

This exact word or phrase:

When looking for a specific result

Any of these words:

Best used for discovery & interchangable words

None of these words:

Recommended to be used in conjunction with other fields

Language:

Dates

Publication Date Range:

to

Document Data

Title:

Document Type:

Library

Collection:

Series:

People

Author:

Help
Clear All

Query Builder

Query box

Help
Clear All

For additional assistance using the Custom Query please check out our Help Page

i

The role of epidemiology in the regulation of oral contraceptives.

  • 1984 Jul-Aug

  • By Sobel, S
  • Source: Public Health Rep. 99(4):350-354
Filetype[PDF-1.09 MB]


  • English
    • Details Related Documents You May Also Like

    Details:

    • Alternative Title:
      Public Health Rep
    • Personal Author:
      Sobel, S
    • Description:
      The U.S. Food and Drug Administration (FDA) has relied to a great degree on epidemiologic studies in the regulation of oral contraceptives (OC). These epidemiologic studies range from individual case reports of adverse reactions to case-control studies and cohort studies. Important findings about adverse reactions to OCs have been communicated through "labeling," which includes information leaflets provided as package inserts for physicians and patients. Also, the FDA communicates its position through publications in medical journals, the FDA Drug Bulletin, public advisory committee meetings, workshops, and symposia. The agency responds to new epidemiologic information; labeling guidelines are under continuing review and revision. Patterns of oral contraceptive use have been affected by the dissemination of this information. There has been a decline in the use of OCs, a shift to formulations with lesser steroidal content, and a greater emphasis on OC use in optimal groups, such as young, nonsmoking women. Considered for future epidemiologic studies that may have an impact on regulatory action are a clarification of the role of various progestins in regard to blood lipid alteration and atherogenesis, a delineation of the possible persistence of cardiovascular risk after termination of OC use, and further clarification in regard to neoplasia, particularly breast and cervical carcinoma.
    • Subject:
    • Source:
      Public Health Rep. 99(4):350-354
    • Pubmed ID:
      6431481
    • Pubmed Central ID:
      PMCnull
    • Document Type:
      Journal Article
    • Name as Subject:
      United States. Food and Drug Administration.
    • Place as Subject:
      United States
    • Collection(s):
      Public Health Reports
    • Main Document Checksum:
    • File Type:

    Supporting Files

    • No Additional Files

    More +

    Related Documents

    You May Also Like

    Checkout today's featured content at stacks.cdc.gov